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Introduction: We assessed the utility of EBC pH as a biomarker in COPD in a large cohort of
well-characterised individuals with COPD and control subjects from the Evaluation of COPD
Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. We also determined
short term reproducibility and the response of EBC to oral prednisolone.
Methods: EBC was collected with R-TubesTM, using techniques for sampling and measurement
that have been shown to be reproducible.
Results: EBC pH was lower in COPD (nZ 676, 7.29  SD 0.60) and in smoking controls (nZ 31,
7.18  0.85), compared with non-smoking controls (n Z 50, 7.59  0.44, p Z 0.0008 and
0.0033 respectively), but was not different between COPD and smoking controls. There was
no relationship between EBC pH and disease severity, as assessed by the percent predicted
FEV1, nor with airway inflammation as assessed by sputum leukocyte counts. Treatment with
20 mg.day-1 prednisolone for 4 weeks did not change EBC pH.
Conclusion: EBC pH is lower in COPD than in healthy control non-smokers, but does not differ-
entiate COPD from smokers without COPD, relate to disease severity or to airway inflamma-
tion, and does not respond to corticosteroids. EBC pH therefore does not appear to be
a useful biomarker in COPD.
ª 2011 Elsevier Ltd. All rights reserved.1 242 6583; fax: þ44 131 242 6582.
uk (W. MacNee).
D Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators.
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Chronic obstructive pulmonary disease (COPD) is charac-
terised by progressive airflow limitation and chronic airway
inflammation. Characterisation of COPD patients has
largely relied on the measurement of airflow limitation, as
assessed by the forced expiratory volume in 1 s (FEV1),
which has been used to assess the effects of therapeutic
interventions in COPD clinical trials. There is a need for
a validated biomarker of the airway inflammation in COPD,
both to aid in characterisation of patients and also to assess
the effects of therapeutic interventions, particularly anti-
inflammatory treatments.
Exhaled breath condensate (EBC) has been used as
a non-invasive technique to assess a range of biomarkers in
a variety of lung diseases including COPD.1 A large number
of studies have shown significant disease-associated
differences in the levels of diverse inflammatory
biomarkers in EBC including cytokines and prostanoids.2
However, these studies have generally been small in
number and employed different methodologies, resulting in
a lack of reproducibility of the findings, variations in the
levels of measured parameters and consequently the data
are difficult to interpret.3
Acidification of the airways, as assessed by EBC pH, is
thought to reflect airway inflammation and EBC pH has
been shown to be low in diverse respiratory diseases
including asthma, COPD, chronic cough, bronchiectasis,
and adult respiratory distress syndrome.4e8
Exhaled breath condensate pH has been reported to
correlatewith other indices of airway inflammation including
sputum neutrophilia4 and to be reduced further in exacer-
bations of COPD in one preliminary study,9 but not in a more
definitive study. EBC pHmeasurements are perhaps themost
validated of all measurements performed on EBC with
subject variability, collection, storage and assay system
variations having been evaluated.10e14 Normative data for
EBC pH have been established in large populations of healthy
subjects,10 although there are still issues with stand-
ardisation ofmethodology and reproducibility of EBCpH.11,12
The validity of EBC pH as a biomarker in COPD patients
has not been fully assessed, as most studies have made
measurements in small numbers of subjects without proper
characterisation of confounding factors, such as smoking
status. We therefore assessed the reproducibility of EBC pH
and the effect of smoking in healthy subjects (Study 1) and
the utility of EBC pH as a potential biomarker in a large,
well-characterised cohort of patients with COPD (Study 2).
In addition we evaluated the sensitivity of EBC pH to anti-
inflammatory treatment with oral corticosteroids (Study 3).
The results of these studies have been previously
reported in abstract form.15,16MethodsStudy 1: reproducibility of EBC pH and effects of
smoking
We assessed the reproducibility of EBC pH in healthy non-
smokers (n Z 6, 2F 4M; mean age 48.8  SD 5.9 years),current smokers (n Z 10, 7F, 3M; mean age 49.8  6.9
years), and healthy ex-smokers (not smoking for >12
months and at least 10 pack years smoking history, n Z 6,
5F, 1M; mean age 57.3  8.1 years) (GSK study number
SB332235/030). Exhaled breath condensate samples were
collected as described previously14 using RTubes (Respi-
ratory Research, Charlottesville, Virginia) at 0, 1, 3, 4, 6
and 8 h beginning at 8am on each study day on each of two
visits. Lunch was provided before the 4 h collection. The
effect of an acute smoking challenge (3 cigarettes) was also
assessed in current smokers at two separate visits. Subjects
attended the unit for a screening visit (Visit 1) within 21
days prior to the study start. Each non-smoking group
attended for two further study visits, 5e10 days apart.
Current smokers attended the clinic for four further study
days. These four visits occurred as two sets of two
consecutive days, 5e10 days apart. Smokers refrained from
smoking from midnight the night before, and during the day
on Visits 1 (screening visit), 2 and 4. To study the acute
effects of smoking, current smokers were allowed to smoke
three cigarettes for 30 min before collection of EBC on
Visits 3 and 5.
Study 2: assessment of EBC pH in the ECLIPSE
cohort
Exhaled breath condensate was obtained in the Evaluation
of COPD Longitudinally to Identify Predictive Surrogate
Endpoints (ECLIPSE) cohort of patients (GSK Study number:
SCO104960; clinicaltrials.gov Identifier NCT 00292552,
appendix I). The aims of the ECLIPSE study and the study
protocol have been previously described.17 In brief,
ECLIPSE is a multicentre, three year longitudinal prospec-
tive study to identify novel endpoints in COPD. Individuals
aged 40e75 years were recruited to the study if they had
a smoking history of 10 pack years, a post-bronchodilator
ratio between forced expiratory volume in 1 s (FEV1) and
forced vital capacity (FVC) 0.7 and an FEV1 % predicted
<80%. Smoking (10 pack years) and non-smoking (<1 pack
year) control subjects were enrolled if they were aged
between 40 and 75 years and had normal lung function
(post-bronchodilator FEV1 >80% and FEV1/FVC ratio >0.7)
(Table 1). Individuals were excluded if they were known to
have PiSZ ZZnul or nulnul alpha-1-antitrypsin deficiency or
a respiratory disorder other than COPD. All subjects
underwent standard spirometry following 180 mg (2 puffs)
of salbutamol.18 Reflux/heartburn were self-reported in
the ATSDLD-78 questionnaire. All measurements were made
in patients at a time of clinical stability (at least six weeks
from the last exacerbation). EBC and induced sputum were
collected at the baseline ECLIPSE visit as described below.
Study 3: effects of oral corticosteroids on EBC pH in
individuals with COPD (GSK study number
RES106087; Clinicaltrials.gov identifier
NCT00379730)
In a study separate from ECLIPSE, current/former smokers
aged 40e80 yrs with a post-salbutamol FEV1 of 30e80%
predicted and an FEV1/FVC ratio of <0.7 (n Z 35, Table 2)
were recruited to study the effects of oral corticosteroids
Table 1 Demographics of the subjects with assessment of exhaled breath condensate (EBC) and the total ECLIPSE population
(ECLIPSE). Data are presented as mean  SD or n (%) unless otherwise indicated.
COPD subjects Smoker controls Non-smoker controls
EBC
(n Z 676)
ECLIPSE
(n Z 2164)
EBC
(n Z 31)
ECLIPSE
(n Z 337)
EBC
(n Z 50)
ECLIPSE
(n Z 245)
Mean age, years 63  7 63  7 58  9 55  9 58  9 54  9
Male, n (%) 433 (64%) 1413 (65%) 20 (65%) 187 (56%) 17 (34%) 92 (37%)
Mean FEV 1, L
a 1.37  0.51 1.35  0.52 3.30  0.83 3.33  0.77 3.15  0.69 3.28  0.79
Mean % predicted FEV1, L
a 49  16 48  16 110  13 109  12 117  13 115  14
Mean FEV1,/FVC, %
a 44  12 45  12 80  6 79  5 80  5 81  5
Current smoker, n (%) 261 (39%) 784 (36%) 10 (32%) 204 (61%) 0 0
Mean pack years 47  28 49  27 27  15 32  21 1b 0.2  1.1
a Values are post-bronchodilator.
b One subject reported prior smoking history.
Exhaled breath condensate pH in COPD 1039on EBC pH and other biomarkers.19 We have recently
reported the effect in this study of corticosteroid therapy
on serum concentrations of surfactant protein D in the
absence of changes in pre- and post-bronchodilator FEV1.
19
Individuals were excluded if they had had an exacerbation
of COPD requiring steroid or antibiotics in the month prior
to the 28-day screening period or were taking oral or
inhaled steroids for 14 days consecutively in the 6 months
prior to screening. Individuals were randomised to receive
either placebo or 20 mg prednisolone day-1 for 4 weeks;
EBC was obtained at baseline and after four weeks treat-
ment with placebo or prednisolone.Exhaled breath condensate
EBC collection was carried out as described previously.14,20
All subjects were asked to refrain from eating, drinking and
smoking (except in those subjects in which the acute
effects of smoking were studied) at least 3 h prior to
collection. EBC samples were obtained prior to lung func-
tion assessments and in those subjects who underwentTable 2 Summary of demographic baseline characteris-
tics of the COPD patients randomised to receive placebo or
oral corticosteroids in Study 3. Data are presented as
mean  SD or n (%) unless otherwise indicated. Subjects had
EBC measured at least once during the study. FVC: forced
vital capacity.
Placebo Prednisolone
Subjects, n 15 20
Age, yrs 61  10 63  11
Males 87% 85%
FEV1 L
a 1.55  0.60 1.61  0.64
FEV1 % predicted
a 53  17 54  15
FEV1/FVC %
a 50  8 48  12
FEV1 reversibility % 10  23 19  12
Smoking history, pack-yrs 48  24 48  29
Current smokers 53% 40%
Salbutamol use 73% 90%
Ipratropium bromide use 33% 40%
a Post-bronchodilator.sputum induction prior to this procedure. EBC samples were
collected during tidal breathing for 10 min, without nose
clips, using the RTubeTM (Respiratory Research Inc, Char-
lottesville, Virginia), aliquoted and stored at 70 C
according to the manufacturer’s instruction (http://www.
rtube.com/products/rtube/overview_htm).
A 200 mL aliquot of EBC was used for the pH assay.
Measurement of pH was performed by a central laboratory
(Respiratory Research Inc, Charlottesville, Virginia for the
healthy subjects study; Cenetron Diagnostics, Austin, Texas
for both COPD studies) after de-aeration by bubbling argon
through the sample at 2 L/min while monitoring pH until the
reading stabilised, usually after 8 min of de-aeration with
argon as described previously.14,21 Amylase was measured in
EBC as an indicator of salivary contamination. Measurable
amylase levels were found in only 3.7% of samples.
EBC samples were kept at 70 until all the baseline
samples had been collected and other baseline data were
available, and were therefore stored at 70 for less than 2
years. A previous study has confirmed the stability of EBC
pH following long-term storage.21
Sputum induction
Sputum induction was performed on 398 subjects from the
same subgroup of COPD patients in the ECLIPSE cohort
(Study 2) who had EBC collected at the baseline visit.
Sputum was induced using 3  7 minute inhalations of 3%
saline. Sputum plugs were extracted and the samples were
processed with dithiotreitol (DTT, 0.1% in distilled water).
PBS was added and the samples were passed through a filter
and centrifuged. Cytospins were prepared from the cell
pellets, air dried, fixed with methanol and stained with
Rapi-diff (Triangle, Skelmersdale, UK). Five hundred
leukocytes were counted by two independent readers at
a central laboratory (Dr Rennard’s laboratory, University of
Nebraska, USA) and the results expressed as a percentage
of the total leucocyte count, and a total cell number/ml.Statistical analysis
In the reproducibility study (Study 1), mixed effects models
were fitted with subject as a random effect and subject
Figure 1 (a). Mean EBC pH over time by Subject Group
(Study 1) healthy current, ex and non-smokers. Healthy current
smokers had abstained from smoking for at least 8 h. There are
no significant differences between the groups. (b). mean EBC
pH over time in healthy current smokers at visits 2 and 4 when
they had abstained from smoking prior to the study (not
smoking) and at visits 3 and 5 when they had smoked 3 ciga-
rettes for 30 min before the collection of EBC (post-smoking).
1040 W. MacNee et al.group, day and time as fixed effects, as needed. Compari-
sons of EBC pH between subject groups were obtained from
the above models by constructing appropriate contrasts. To
investigate the acute change in EBC pH and variability in
response to cigarette smoke, a mixed effects model was
fitted with visit and time as fixed effects and subject as
a random effect. The model allowed for unequal variances
pre- and post-smoking. The difference in the EBC pH whenTable 3 Within and between subject variability in EBC pH (Stu
Assessment day Group
Days 1 and 2 Healthy non-smokers
Current smokers
Healthy ex-smokers
Day 1 only Healthy non-smokers
Current smokers
Healthy ex-smokers
Day 2 only Healthy non-smokers
Current smokers
Healthy ex-smokersabstaining from smoking (ie, Visits 2 and 4) and post-
smoking (ie, Visits 3 and 5) was calculated by constructing
the appropriate contrast.
In study 2, sample sizes of 676 COPD subjects and 31
smoker controls (50 non-smoker controls) provided 89%
(97%) power to detect a difference of 0.5 between the two
groups based on a two-sided T-test with a Z 0.05 and an
assumed standard deviation of 0.85. Statistical analysis in
the ECLIPSE cohort (Study 2) was performed by ANOVA and
pairwise comparisons.
The ShapiroeWilk test indicated that the distribution of
pH was non-normal. Thus Spearman correlation coefficients
were calculated to investigate the relationship between
EBC pH and induced sputum cell counts.
In the prednisolone study (Study 3), the effect of pred-
nisolone on EBC pH and FEV1 was analysed by ANOVA,
adjusting for baseline value and study site.
Ethics
The studies were all conducted in accordance with the
declaration of Helsinki and ICH Good Clinical Practice
guidelines and were approved by the relevant Ethics and
Institutional Review Boards at the participating centres.
Results
Study 1: reproducibility of EBC pH and effects of
smoking
Exhaled breath condensate pH was highly reproducible in
almost all subjects (CV range 1e14%), bothwithin a given day
and on separate visits (Fig. 1a and Table 3). However, a small
number of subjects revealed variability on one ormore visits,
usually post-prandially at the 4 h time point (Fig. 1a), a trend
that persisted at the 6 h collection in some subjects. The
within-subject variance of pH was not affected by subjects
being allowed to smoke (0.0721 when abstained from
smoking, compared to 0.0750 when allowed to smoke).
When EBC pHwas compared across groups of subjects who
were not allowed to smoke, no statistically significant
differences were observed (data not shown). In the current
smoker population, EBC pH was significantly higher when
subjects abstained from smoking compared with post-dy 1).
Variability estimates
Within-subject Between-subject
0.0444 0.0444
0.0774 00962
0.0382 0.0475
0.0265 0.0346
0.1122 0.1543
0.0303 0.0441
0.0386 0.0492
0.0401 0.0457
0.0096 0.0256
Figure 2 EBC pH values in non-smoker and smoker controls
and COPD patients. Vertical bars represent median and inter-
quartile range (C: mean;B: outliers). Mean EBC pH was lower
in patients with COPD, compared with non-smoker controls
(p Z 0.0008) and in smoker controls versus non-smoker
controls (p Z 0.0033). The difference between COPD patients
and smoker controls was not significant (p Z 0.33).
Exhaled breath condensate pH in COPD 1041smoking EBC pH (mean treatment difference: 0.16; 95% CI:
0.01, 0.31). Mean EBC pH values are graphically represented
in Fig. 1b.
In the current smoker population, excluding those with
a positive carbon monoxide breath test (exhaled breath
carbon monoxide level of 10 ppm) at baseline, results
were similar to those obtained with all current smokers
included in the analysis (treatment difference 0.24; 95% CI:
0.10, 0.38).
Study 2: assessment of EBC pH in the ECLIPSE
cohort
Exhaled breath condensate pH was measured in samples
from 757 individuals (676 COPD patients, 31 smoker controls
and 50 non-smoker controls). The demographics of the
exhaled breath cohort were similar to those of the entire
population of subjects enrolled in the ECLIPSE study, with
the exception that in the smoking controls there were less
current smokers and more males in the EBC cohort than in
the full ECLIPSE cohort (Table 1).
A significantly lower mean EBC pH was observed in
patients with COPD, compared with non-smoker controls
(p Z 0.0008) and in smoker controls versus non-smoker
controls (p Z 0.0033). The difference between COPD
patients and smoker controls was not significant (pZ 0.33)
(Fig. 2).
When COPD patients and smoker control subjects were
divided according to smoking status (current versus former
smokers), EBC pH was significantly lower in all smoker
groups compared to non-smoker controls. There was,
however, no difference between COPD, whether current or
ex-smokers, and smoker controls (Fig. 3a). When COPD
subjects were categorised according to GOLD stage,22 there
was no relationship between EBC pH and disease severity as
assessed by the FEV1 % predicted (Fig. 3b).
Stratification of the COPD subjects and controls
according to the presence or absence of gastro oesophageal
reflux showed no significant differences in EBC pH. Nor
were there any significant differences in EBC pH betweenpatients who did or did not receive treatment with inhaled
corticosteroids or long acting beta agonists.
A subgroup of 389 subjects had both EBC and sputum
sampled and had demographics which were not different
from the ECLIPSE cohort as a whole (data not shown). In this
group there was no relationship between EBC pH and
airway inflammation as assessed by sputum leukocyte
counts (eosinophils, lymphocytes or neutrophils, rZ 0.052,
0.027, 0.080, respectively, p > 0.05).
Study 3: effects of oral corticosteroids on EBC pH in
individuals with COPD
A total of 35 current or former smokers diagnosed with
COPD were recruited and randomised to receive either oral
prednisolone or placebo for four weeks. The groups were
well matched for age, sex, lung function and smoking
history (Table 2). At baseline EBC pH values were lower in
the placebo group than in the prednisolone treated group,
possibly as a result of a higher percentage of current
smokers than in the prednisolone group(53% vs 40%), which
could have resulted in lower EBC pH values.
There were three withdrawals in the prednisolone group
and two in the placebo group during the course of the
study. Treatment with prednisolone resulted in a small
increase relative to placebo in pre- and post-bronchodilator
FEV1 (compared to trough) of 41 and 74 mL, respectively;
neither of these changes were statistically significant
(p > 0.5 for both). There was no change in EBC pH after
treatment with prednisolone (Fig. 4).
Discussion
Exhaled breath condensate (EBC) is a method of sampling
the air from the airways non-invasively that is easily
repeated and acceptable to patients. As the expired air is
cooled, water vapour condenses and then traps volatile
substances evolving from the airway lining fluid. When the
airway lining source fluid is acidic, there is more proton-
ation of anions into unchargeddand volatiledacids, which
are then more readily exhaled and captured, reducing the
pH of the EBC. Guidelines on the use of EBC have been
published by the European Respiratory Society Task
Force.23
In assessing the potential of EBC pH as a biomarker in
COPD the following ideal characteristics of a pulmonary
biomarker should be assessed 1) reproducibility; 2) disease
specificity; 3) the ability of biomarkers to differentiate
between health and disease; 4) the ability of the biomarker
to distinguish different severities and phenotypes of
disease, and 5) the ability of the biomarker to change
following an intervention.
Acidification of the airways is thought to reflect airway
inflammation. A study of >400 healthy subjects has defined
an “normal range” for EBC pH where the median pH was
8.010 In Study 1, EBC pH was highly reproducible in almost
all subjects, both within a given day and on separate visits,
in accordance with reported evidence of EBC pH repro-
ducibility.14 There was a post-prandial reduction in EBC pH
in several individuals (possibly due to gastro-oesophageal
reflux or ingestion of acidifying foods). Thus in subsequent
Figure 3 EBC pH values in COPD and controls according to (a) smoking history. EBC pH was significantly lower in all smoker groups
compared to non-smoker controls (p  0.028), but no difference between COPD, whether current or ex-smokers and smoker
controls. (b) EBC pH values in COPD according to disease severity as assessed by GOLD stage. There are no significant differences
between the groups. Vertical bars represent median and interquartile range (C: mean; þ: outliers). Smkr ctrl Z smoker control
subject; FS Z former smoker; CS Z current smoker.
1042 W. MacNee et al.studies we did not collect EBC for at least 2 h after
consuming anything other than water. There was an acute
effect of smoking on EBC pH. Thus in subsequent studies we
asked subjects to abstain from smoking for at least 3 h prior
to EBC collection to reduce assay variability due to the
acute effects of smoking.Figure 4 Effects of placebo or prednisolone on EBC pH in
COPD patients. Vertical bars represent the median and inter-
quartile range (þ: outliers) and the horizontal lines the
medians. There are no significant changes in EBC pH after
prednisolone (Pred) or placebo (Pbo).The factors that influence the reproducibility of EBC pH
have been studied previously in COPD patients.11 These
studies showed that COPD patients have a higher within and
between day variability in EBC pH than normal subjects and
that measurements change over time in COPD patients for
reasons which are not clear, but may relate to several
factors, such as airway inflammation, oxidative stress,
gastroesophogeal reflux and bacterial colonisation, which
are known to influence EBC pH.14
Weused the established techniquewhich employed Argon
de-aeration to remove all volatile components of EBC
allowing the measurement of non volatile acidity. More
recent studies have suggested that this technique may not
removeCO2whichmay influence the valueof EBCpHand that
measurement of pH at a standard CO2 partial pressure may
improve the reproducibility of the measurement.24 However
we were able to establish good reproducibility of pH
measurements using the technique which we employed.
In Study 2, we have confirmed the results of previous
studies in smaller groups of patients4,11 that patients with
COPD have reduced EBC pH. However, there is considerable
overlap between COPD subjects and normal non-smokers.
This contrasts with previous studies which have suggested
a clear differentiation between the EBC pH normal range
and the EBC pH observed in COPD patients.4 An important
strength of Study 2 is that the relatively large sample size
provides a much better indication of the true distribution of
EBC pH than is possible in smaller studies. Previous studies
have shown marked overlap between the results obtained
in COPD and other airways diseases such as asthma4,20 and
cystic fibrosis25 and have also not taken into account con-
founding factors in COPD patients, such as the effects of
cigarette smoking. We also found that cigarette smokers
without COPD also had acidification in their airways with
lower EBC pH than healthy normal subjects, but found no
difference in EBC pH between smoker controls and COPD
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Exhaled breath condensate pH in COPD 1043subjects. Furthermore, when subjects were separated
according to their smoking status (current versus former
smokers), EBC pH was significantly lower in all smoking
groups compared to non-smoking controls. There was no
difference between COPD patients divided by smoking
status and smoker controls; however ex-smokers with COPD
did retain lower EBC pH than healthy non-smokers.
We studied the influence of the presence of gastro
oesophageal reflux on EBC pH and found no differences in
EBC pH in those with or without reported gastro oesopha-
geal reflux. In addition treatment with inhaled corticoste-
roids or long acting beta agonists did not appear to
influence EBC pH.
A previous study in a small group of patients has shown
a relationship between EBC pH and disease severity as
measured by the FEV1,
4 although this was not confirmed in
another COPD population.11 In Study 2, in a large group of
COPD patients, no relationship between EBC pH and disease
severity as measured by the FEV1 was found.
Exhaled breath condensate is thought to reflect airway
inflammation and, indeed, in a small study a relationship
was shown between EBC pH and sputum neutrophils.4
However in Study 2, in a large group of COPD patients,
we were unable to find any relationship between airway
inflammation as assessed by sputum leukocyte counts and
EBC pH. In a previous cross sectional study in COPD patients
EBC pH was not different whether patients were treated or
not with inhaled corticosteroids.4 We were also unable to
show an effect of the anti-inflammatory agent prednisolone
on EBC pH (Study 3). This contrasts with a previous study in
the same patients in which prednisolone reduced the levels
of surfactant protein-D, a marker of airway inflammation/
injury.19
In summary, EBC pH distinguished smoker controls and
COPD patients from non-smoker controls, but did not
distinguish smoker controls from COPD patients. We found
no differences in EBC pH related to disease severity, nor
a relationship between EBC pH and airway inflammation as
assessed by sputum leukocyte counts. EBC pH was not
affected by treatment with an oral corticosteroid. When
taken together, these data suggest that EBC pH does not
distinguish COPD subjects from current/former smokers
with normal lung function and is not useful as a biomarker
for assessment of disease severity or the effect of inter-
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